Prognoza
Średnia cena docelowa analityków wynosi 100,77 € (+419,97%). Mediana wynosi 132,02 € (+581,22%).
| Kupuj |
5 |
| Trzymaj |
0 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Bright Minds Biosciences raises $175 million through placement of common shares
Bright Minds Biosciences placed 1,945,000 common shares at $90.00 each, generating gross proceeds of $175.05 million. The syndicate banks were granted a 30-day overallotment option for up to 291,750 additional shares. The funds are intended to finance clinical trials (including the start of phase 1 for BMB-105), research and development of earlier programs, and general corporate purposes. » Więcej na de.investing.com
Bright Minds Biosciences sets price for share offering at $90
Bright Minds Biosciences has set the price for a public offering of 1,945,000 common shares at $90.00 per share and expects gross proceeds of about $175.05 million. The underwriters were granted a 30-day option to purchase up to 291,750 additional shares at the same price; closing is expected on January 9, 2026. The proceeds are intended to fund clinical trials for several drug candidates; the company has simultaneously ended its at-the-market program. Analysts mostly rate the stock as "Buy," and the share price and market capitalization have risen sharply after a strong rally. » Więcej na de.investing.com
Bright Minds Biosciences plans public offering of $100 million
Bright Minds Biosciences announced a public offering of common stock and pre-funded warrants totaling $100 million and granted the underwriters a 30-day option to purchase up to 15% of the offered common stock. Proceeds are intended to fund clinical trials for drugs targeting absence seizures, DEE and Prader‑Willi syndrome, as well as Phase 1 studies for BMB‑105, earlier-stage research and general corporate purposes. The offering is being made under an F-3 registration; Jefferies, TD Cowen, Piper Sandler and Cantor are serving as joint book-running managers. The company reports a strong balance sheet with more cash than debt and a current ratio of 36.1. » Więcej na de.investing.com
Bright Minds Biosciences stock rises after positive phase‑2 data on BMB‑101
The stock of Bright Minds Biosciences rose about 5% after positive topline results from the phase‑2 BREAKTHROUGH study of the selective 5‑HT2C agonist BMB‑101 in epilepsy‑associated disorders. In the 24‑patient study, median seizure frequency in absence epilepsy fell by 73.1% (p=0.012) and severe motor seizures in DEE patients by 63.3%. BMB‑101 also significantly improved REM sleep, was mostly well tolerated and showed no treatment‑related serious adverse events. Bright Minds is preparing global registration trials for DEE and absence epilepsy and plans a study in Prader‑Willi syndrome in Q1 2026. » Więcej na de.investing.com
Bright Minds launches Prader‑Willi program and nominates BMB-105 as clinical candidate
Bright Minds has launched a Prader‑Willi syndrome (PWS) program and nominated BMB-105 as a new clinical candidate. The company is starting the double‑blind, randomized phase‑2a NOVA study with BMB-101 to evaluate efficacy and safety in PWS patients and plans a parallel randomized, placebo‑controlled phase‑1 study of BMB-105 in healthy volunteers. BMB-101 has shown good tolerability so far in epilepsy studies, with top‑line data expected in January 2026; Bright Minds aims to accelerate time to market by roughly one year with BMB-105. » Więcej na de.investing.com
Dane finansowe
W ostatnim kwartale BRIGHT MINDS BIOSCIENCES osiągnęła przychody w wysokości 0 € i zysk netto w wysokości -1,52 mln €
| (EUR) | czerwiec 2026 | YoY |
|---|---|---|
| Przychody | 0 | - |
| Zysk brutto | -12,32 tys. | - |
| Zysk netto | -1,52 mln | 53,56% |
| EBITDA | -7,22 mln | 121,62% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 189,68 mln € |
Liczba akcji | 9,86 mln |
Maksimum/minimum z 52 tygodni | 112,67 € - 15,84 € |
| Dywidendy | Nie |
Beta | 0,09 |
C/Z (PE Ratio) | -9,97 |
PEG (PEG Ratio) | 0,13 |
C/WK (PB Ratio) | 0,92 |
C/S (PS Ratio) | 0,00 |
Profil spółki
Bright Minds Biosciences Inc., firma bionaukowa będąca na etapie badań przedklinicznych, opracowuje leki oparte na serotoninie (5-HT), które mają poprawić życie pacjentów z ciężkimi chorobami zmieniającymi życie. Jej portfel selektywnych agonistów receptorów 5-HT obejmuje 5-HT2C, 5-HT2A oraz 5-HT2C/A i jest przeznaczony do leczenia padaczki, bólu oraz zaburzeń neuropsychiatrycznych. Firma współpracuje z National Institutes of Health w zakresie leczenia padaczki, z University of Texas Medical Branch w celu leczenia zaburzeń kontroli impulsów, takich jak napadowe objadanie się, oraz z Medical College of Wisconsin. Spółka została założona w 2019 roku i ma siedzibę główną w Vancouver w Kanadzie.
| Nazwa | BRIGHT MINDS BIOSCIENCES |
| CEO | Ian McDonald |
| Siedziba | New York,
ny Kanada |
| Strona internetowa | |
| Sektor | Materiały podstawowe |
| Branża | Chemikalia |
| Debiut giełdowy | 22.03.2021 |
| Pracownicy | 26 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | DRUG |